Copy Link Print Information

TBK1 Antibody (YA040)

(Synonyms: TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1)
Customer Review

Based on 1 Customer Validation

TBK1 Antibody (YA040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB

  • Reactivity :

    Human, Mouse, Rat, Hamster

  • Formulation:

    Supplied in 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol and 0.05% BSA. Preservative: 0.01% Sodium azide

  • Conjugation:
    Non-conjugated
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • TBK1 Antibody (YA040) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
You May Still Need
Top Publications Citing

Use of MCE Products

Applications

Application
WB Info
WB: Western Blot
Dilution Ratio 1:500-1:1000

Product Details

Description

TBK1 Antibody (YA040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

  • Host Rabbit
  • Clonality Recombinant,Monoclonal
  • Species Reactivity
    Human, Mouse, Rat, Hamster
  • Observed Molecular Weight
    Observed band size: 84 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 84 kDa
Species Reactivity Database
Immunogen

Synthetic peptide corresponding to Human TBK1.The exact sequence is proprietary to MCE.

Sensitivity

Endogenous

Purification

affinity purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3102748

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol and 0.05% BSA. Preservative: 0.01% Sodium azide

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for TBK1 Antibody (YA040)
    Western blot analysis of extracts from 293T using TBK1 antibody. Proteins were transferred to a PVDF membrane and blocked with 5% nonfat powdered milk in PBST for 2 hour at room temperature. The primary antibody (1/1000) and loading control antibody (GAPDH, 1/3000) was diluted with 5% nonfat powdered milk in PBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (1/8,000) was incubated for 45min at room temperature.
  • Experimental Validation Results for TBK1 Antibody (YA040)
    Western blot analysis was performed on extracts from Hela (lane 1, 15 μg), HepG2 (lane 2, 15 μg), 293T (lane 3, 15 μg), CHO-K1 (lane 4, 15 μg), 3T3 (lane 5, 15 μg), and C6 (lane 6, 15 μg) using NAK/TBK1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:10000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

Background

  • Function

    TANK-binding kinase 1 (TBK1) is a serine/threonine kinase central to innate immune signaling, mediating phosphorylation of IRF3/7 to induce type I interferon (IFN) and interferon-stimulated genes (ISGs) [1][2]. Mechanistically, TBK1 participates in antiviral defense via the RIG-I-like receptor (RLR) and TLR pathways, promoting IRF3 nuclear translocation and IFN-β production[3][4][5]. Alternative splicing generates TBK1 isoforms that can negatively regulate antiviral responses by disrupting TBK1-IRF3 interactions, facilitating proteasomal degradation of TBK1 and lysosomal degradation of IRF3[3][4][6][5]. TBK1 also supports AKT/mTORC1 pathway activation in cancer, influencing cellular proliferation and survival, with context-dependent effects in KRAS-mutant lung cancers[7][2]. Dysregulated TBK1 activity is associated with autoimmune diseases, interferonopathies, and cancer, highlighting its therapeutic relevance[1][8][9]. Pharmacological inhibition using small molecules such as BX795 and amlexanox modulates TBK1-mediated signaling, suppressing inflammation, cellular senescence, and IFN production in disease models, while agonists of downstream effectors like IRF3 can enhance antiviral responses[10][11][8]. Compared with related kinases, TBK1 demonstrates isoform-specific regulation of IFN signaling and unique interactions with viral or cellular substrates, distinguishing its function from IKKε and other IKK family members[12][13]. High-throughput assays and computational QSAR models have facilitated the discovery of selective TBK1 inhibitors, providing tools for experimental modulation of innate immune and oncogenic pathways[12][14]. Collectively, TBK1 acts as a central hub in innate immunity, cancer biology, and inflammatory regulation, with isoform-specific roles and pharmacological manipulability informing research design[2][15].

  • Subcellular Localization

    Cytoplasm

  • Expression


    Tissue_specificity:It is widely distributed throughout the body, with higher expression in the testes. It is also expressed in ganglion cells, nerve fiber layers, and microvessels of the retina.

  • Subunit

    Homodimer (PubMed:21145761, PubMed:37926288). Interacts with DDX3X, TIRAP and TRAF2 (PubMed:10581243, PubMed:14530355). Part of a ternary complex consisting of TANK, TRAF2 and TBK1 (PubMed:10581243). Interacts with AZI2, TANK and TBKBP1; these interactions are mutually exclusive and mediate TBK1 activation (PubMed:10581243, PubMed:14560022, PubMed:21931631, PubMed:23453972, PubMed:29251827). Interacts with GSK3B; this interaction promotes TBK1 self-association and autophosphorylation (PubMed:21145761). Interacts with SIKE1; SIKE1 is associated with TBK1 under physiological condition and dissociated from TBK1 upon viral infection or TLR3 stimulation (PubMed:16281057). Interacts with IRF3, leading to IRF3 phosphorylation (PubMed:14703513, PubMed:25636800, PubMed:37926288). Interacts with RIGI (PubMed:16281057). Interacts with CYLD (PubMed:18636086, PubMed:32185393). Interacts with OPTN and TRAF3 (PubMed:20174559). Interacts with SRC (PubMed:19419966). Interacts with the exocyst complex subunit SEC5/EXOC2; this interaction is sufficient to trigger TBK1 activity (PubMed:17018283). Interacts with STING1, leading to STING1 phosphorylation (PubMed:19416887, PubMed:25636800, PubMed:30842653). Interacts with IFIT3 (via N-terminus) (PubMed:21813773). Interacts with MAVS; interaction only takes place in the presence of IFIT3 and leads to MAVS phosphorylation (PubMed:21813773, PubMed:25636800, PubMed:28011935, PubMed:37926288). Interacts (via protein kinase domain) with TTLL12 (via TTL domain); the interaction prevents MAVS binding to TBK1 (PubMed:28011935). Interacts with TICAM1; this interaction is enhanced in the presence of WDFY1 and leads to TICAM1 phosphorylation (PubMed:14530355, PubMed:14739303, PubMed:25636800, PubMed:25736436). Interacts with TRIM26 (PubMed:26611359). Interacts with TRIM23 (PubMed:28871090). Interacts with TTC4 and IKBKE (PubMed:29251827). Interacts with HNRNPA2B1 (PubMed:31320558). Interacts with DDX3X (PubMed:20375222). Interacts with TRIM14 (PubMed:32404352). Interacts with CEP170; efficient complex formation may be dependent on the presence of CCDC61 (PubMed:30354798). Interacts with TRAF3IP3 (PubMed:32366851). Interacts with HSP90AA1; the interaction mediates TBK1 association with TOMM70 (PubMed:20628368). Interacts with TAX1BP1 (PubMed:33226137). Interacts with kinase IKBKB; the complex interacts with STAT1, leading to phosphorylation of STAT1 on 'Thr-749' by IKBKB (PubMed:32209697). Interacts with ICOS; this interaction is critical for the maturation of T follicular regulatory cells (PubMed:27135603). Interacts with RNF144B; this interaction prevents TBK1 phosphorylation and subsequent activation (PubMed:31509299). Interacts with ASB8; this interaction promotes TBK1 proteasomal degradation (PubMed:32298923). Forms a ternary complex with ZNF268 and SETD4; the interaction with SETD4 is ZNF268-dependent and leads to TBK1 monomethylation, which enhances its interaction with IRF3 and MAVS (PubMed:37926288)

  • SwissProt ID

    Q9UHD2

  • Gene ID
    29110 [NCBI]
  • Synonyms

    TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1

  • Research Field

    Signal Transduction

[1]. Zhang J, et al. A Novel Transcript Isoform of TBK1 Negatively Regulates Type I IFN Production by Promoting Proteasomal Degradation of TBK1 and Lysosomal Degradation of IRF3. Front Immunol. 2020 Sep 30;11:580864. [Content Brief]

[2]. Hu YW, et al. TANK-Binding Kinase 1 (TBK1) Isoforms Negatively Regulate Type I Interferon Induction by Inhibiting TBK1-IRF3 Interaction and IRF3 Phosphorylation. Front Immunol. 2018 Jan 30;9:84. [Content Brief]

[3]. Zhang J, et al. TBK1 Isoform Inhibits Grass Carp Reovirus Infection by Targeting the Degradation of Viral Nonstructural Proteins NS80 and NS38. J Immunol. 2023 Jan 15;210(2):191-203. [Content Brief]

[4]. Hasan M, et al. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res. 2016 Sep;111:336-342. [Content Brief]

[5]. Ji W, et al. TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases. PLoS Negl Trop Dis. 2023 Jan 10;17(1):e0011001. [Content Brief]

[6]. Zhang M, et al. Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy. Front Immunol. 2022 Sep 12;13:954129. [Content Brief]

[7]. Cooper JM, et al. TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer. Cancer Res. 2017 Sep 15;77(18):5077-5094. [Content Brief]

[8]. Hutti JE, et al. Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε. PLoS One. 2012;7(7):e41494. [Content Brief]

[9]. Yeo SK, et al. AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer. Autophagy. 2024 Mar;20(3):525-540. [Content Brief]

[10]. Deng W, et al. Negative regulation of virus-triggered IFN-beta signaling pathway by alternative splicing of TBK1. J Biol Chem. 2008 Dec 19;283(51):35590-7. [Content Brief]

[11]. Runde AP, et al. The role of TBK1 in cancer pathogenesis and anticancer immunity. J Exp Clin Cancer Res. 2022 Apr 9;41(1):135. [Content Brief]

[12]. Ivanov JM, et al. In Silico Insights: QSAR Modeling of TBK1 Kinase Inhibitors for Enhanced Drug Discovery. J Chem Inf Model. 2024 Oct 14;64(19):7488-7502. [Content Brief]

[13]. Lu R, et al. TBK1 pharmacological inhibition mitigates osteoarthritis through attenuating inflammation and cellular senescence in chondrocytes. J Orthop Translat. 2024 Jun 28;47:207-222. [Content Brief]

[14]. Hui L, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clin Exp Immunol. 2025 Jan 21;219(1):uxae082. [Content Brief]

[15]. Ding C, et al. Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway. Acta Pharm Sin B. 2020 Dec;10(12):2272-2298. [Content Brief]

View More

TBK1 Antibody (YA040) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedchemExpress Validation
     Western blot analysis of extracts from 293T using TBK1 antibody. Proteins were transferred to a PVDF membrane and blocked with 5% nonfat powdered milk in PBST for 2 hour at room temperature. The primary antibody (1/1000) and loading control antibody (GAPDH, 1/3000) was diluted with 5% nonfat powdered milk in PBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (1/8,000) was incubated for 45min at room temperature.

  • 1/16

    MedchemExpress Validation
     Western blot analysis was performed on extracts from Hela (lane 1, 15 μg), HepG2 (lane 2, 15 μg), 293T (lane 3, 15 μg), CHO-K1 (lane 4, 15 μg), 3T3 (lane 5, 15 μg), and C6 (lane 6, 15 μg) using NAK/TBK1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:10000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

  • TBK1 Antibody (YA040) Product Image
    1/16
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • TBK1 Antibody (YA040) Product Image
  • Experimental Validation Results for TBK1 Antibody (YA040)
    1/1
    MedchemExpress Validation
     Western blot analysis of extracts from 293T using TBK1 antibody. Proteins were transferred to a PVDF membrane and blocked with 5% nonfat powdered milk in PBST for 2 hour at room temperature. The primary antibody (1/1000) and loading control antibody (GAPDH, 1/3000) was diluted with 5% nonfat powdered milk in PBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (1/8,000) was incubated for 45min at room temperature.
  • Experimental Validation Results for TBK1 Antibody (YA040)
    1/1
    MedchemExpress Validation
     Western blot analysis was performed on extracts from Hela (lane 1, 15 μg), HepG2 (lane 2, 15 μg), 293T (lane 3, 15 μg), CHO-K1 (lane 4, 15 μg), 3T3 (lane 5, 15 μg), and C6 (lane 6, 15 μg) using NAK/TBK1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:10000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • Experimental Validation Results for TBK1 Antibody (YA040)
  • TBK1 Antibody (YA040) Product Image
    MedchemExpress Validation

    Western blot analysis of extracts from 293T using TBK1 antibody. Proteins were transferred to a PVDF membrane and blocked with 5% nonfat powdered milk in PBST for 2 hour at room temperature. The primary antibody (1/1000) and loading control antibody (GAPDH, 1/3000) was diluted with 5% nonfat powdered milk in PBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (1/8,000) was incubated for 45min at room temperature.

  • TBK1 Antibody (YA040) Product Image
    MedchemExpress Validation

    Western blot analysis was performed on extracts from Hela (lane 1, 15 μg), HepG2 (lane 2, 15 μg), 293T (lane 3, 15 μg), CHO-K1 (lane 4, 15 μg), 3T3 (lane 5, 15 μg), and C6 (lane 6, 15 μg) using NAK/TBK1 Rabbit mAb.Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST at 4°C overnight.The primary antibody (1:1000 dilution) and the loading control antibody (beta-Tubulin, HY-P80955, 1:10000 dilution) were incubated in 5% non-fat milk in TBST for 1 hour at 37°C.Goat Anti-Rabbit IgG-HRP Secondary Antibody (1:20000 dilution) was then applied for 40 minutes at 37°C.

  • TBK1 Antibody (YA040) Product Image WB
  • TBK1 Antibody (YA040) Product Image WB